Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seclidemstat in Relapsed/Refractory Ewing Sarcoma and Select Sarcomas
NCT03600649Phase 1Active, not recruiting
- Sponsor
- Salarius Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Seclidemstat in Ewing sarcoma, myxoid liposarcoma (MLPS), desmoplastic small round cell tumor (DSRCT) and 6 more (3 arms), sponsored by Salarius Pharmaceuticals. Primary endpoint: Safety and tolerability of seclidemstat up to 24 months. Started Jun 2018; status: active, not recruiting.
02
Drugs
Seclidemstat
03
Conditions
Ewing sarcomamyxoid liposarcoma (MLPS)desmoplastic small round cell tumor (DSRCT)extraskeletal myxoid chondrosarcoma (EMC)angiomatoid fibrous histiocytoma (AFH)
Beyond the preview
Go deeper on NCT03600649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03600649.